United States · Platforms & data · MarketBeat

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

Published by MarketBeat · United States 2 h ago

LB Pharmaceuticals (NASDAQ:LBRX) outlined its clinical and commercial plans for LB-102, an investigational antipsychotic designed as a structural modification of amisulpride,…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

The Motley Fool

Dutch Bros vs. Kimberly-Clark: Which Is the Smarter Buy Today?

MarketWatch

A leading Silicon Valley cheerleader just showed all the reasons to be worried about the AI bubble

Investing.com

LB Pharmaceuticals Eyes 2027 Phase III Data for LB-102 in Schizophrenia

Share

Also worth reading

Dutch Bros vs. Kimberly-Clark: Which Is the Smarter Buy Today?

A leading Silicon Valley cheerleader just showed all the reasons to be worried about the AI bubble

Why is SK Hynix stock surging today?

Myro (MYRO) Price Prediction: 2025, 2026, 2030

Popular crypto stock surges as Q3 earnings top estimates

Novartis Raises Guidance After Trial Setbacks Hit Profit